10q10k10q10k.net
Charles River Laboratories

Charles River LaboratoriesCRLEarnings & Financial Report

NYSE · Health Care · Life Sciences Tools & Services

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

CRL Q4 2025 Key Financial Metrics

营收

$994.2M

毛利润

N/A

营业利润

$-283.4M

净利润

$-276.6M

毛利率

N/A

营业利润率

-28.5%

净利率

-27.8%

同比增长

-0.8%

EPS

$-5.57

资金流向

Charles River Laboratories Q4 2025 Financial Summary

Charles River Laboratories reported revenue of $994.2M for Q4 2025, with a net profit of $-276.6M (-27.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$994.2M
Net Profit$-276.6M
Gross MarginN/A
Operating Margin-28.5%
Report PeriodQ4 2025

Charles River Laboratories Annual Revenue by Year

Charles River Laboratories annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.0B).

YearAnnual Revenue
2025$4.0B
2024$4.0B
2023$4.1B
2022$4.0B

利润表

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
营收$1.01B$1.03B$1.01B$1.00B$984.2M$1.03B$1.00B$994.2M
同比增长N/A-0.3%-4.7%N/A-2.7%0.6%-0.5%-0.8%

资产负债表

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
总资产$8.15B$7.95B$8.00B$7.53B$7.58B$7.56B$7.51B$7.14B
总负债$4.45B$4.18B$4.18B$4.02B$4.34B$4.16B$4.06B$3.92B
股东权益$3.64B$3.72B$3.78B$3.46B$3.19B$3.35B$3.41B$3.16B

现金流量表

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
经营性现金流$129.9M$193.5M$251.8M$159.4M$171.7M$204.6M$213.8M$147.5M